There’s a big change for this year’s flu shot: When should you be vaccinated?
GSK is advancing a new mRNA flu vaccine to Phase III trials after the candidate outperformed standard vaccinations in earlier testing.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
GlaxoSmithKline (GSK) has announced the advancement of its mRNA-based influenza vaccine into Phase III, which represents the late-stage trial phase of clinical development. This transition follows data indicating that the mRNA candidate outperformed standard flu shots in previous testing rounds. The move signifies a shift in the company's approach to seasonal respiratory vaccines, moving toward the messenger RNA platform that has become prominent in recent years. This development is occurring as the healthcare industry evaluates the timing and efficacy of vaccination schedules for the current season. Coverage of this development is widespread across financial and medical reporting outlets.
Reuters and Pharmaceutical Executive have both confirmed the progression of the vaccine to late-stage trials. Finance.Yahoo.com highlights the competitive nature of this move, noting that GSK intends to compete directly with Moderna in the mRNA space. Additionally, Fierce Biotech reports that the decision to enter Phase III was driven by the vaccine's ability to beat the results of standard shots, while Cleveland.com addresses the practical implications for patients regarding when they should be vaccinated given changes to this year's flu shot landscape. Contextually, this shift is significant because it pits a traditional vaccine giant like GSK against established mRNA specialists. The move to Phase III trials is the final major hurdle before a product can be submitted for regulatory approval and widespread public use.
For the general public, the transition toward mRNA technology may alter the perceived efficacy and timing of annual vaccinations. The competition between GSK and Moderna suggests a broader industry trend toward adopting genetic sequencing platforms for seasonal viruses to improve the speed and precision of vaccine responses. Future developments to monitor include the specific results and endpoints of the Phase III trials as GSK continues its late-stage testing. Observers will be looking for data that confirms whether the superior performance seen in earlier phases is maintained across a larger, more diverse patient population. Additionally, coverage will likely focus on how the timing of vaccination recommendations changes if the mRNA platform proves to be more effective or longer-lasting than the standard shots currently available to the public.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 75d ago.
Quick answers
What phase of testing is the GSK mRNA flu vaccine entering?
The vaccine is advancing to Phase III, which is the late-stage trial phase.
Which company is GSK expected to compete with using this technology?
According to finance.yahoo.com, GSK hopes to take on Moderna.
Why is GSK moving the vaccine to Phase III trials?
Fierce Biotech reports the vaccine is moving forward after it beat standard shots in earlier testing.
Coverage (7)
- New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine Arab News · 75d ago
- GSK’s Pivotal Test for mRNA Vaccine Aims to Show Two Targets Are Better Than One medcitynews.com · 75d ago
- GSK Advances mRNA Flu Vaccine to Phase III Pharmaceutical Executive · 75d ago
- GSK to advance mRNA flu vaccine to late-stage trial Reuters · 75d ago
- GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial finance.yahoo.com · 75d ago
- GSK catches phase 3 fever after mRNA flu vaccine beats standard shots Fierce Biotech · 75d ago
- There’s a big change for this year’s flu shot: When should you be vaccinated? Cleveland.com · 75d ago
Topics
Related trends
Why the simple flu shot could be a surprise weapon against cancer
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
It’s not too late to get it: what to know about getting the flu vaccine this year
Health officials across multiple states are urging flu vaccinations before Thanksgiving as respiratory viruses begin to increase and 74% of Americans plan holiday gatherings.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The US Food and Drug Administration and Health Canada have approved bepirovirsen, marketed as Hibsago, as the first functional cure for chronic hepatitis B.
Moderna swings to profit as momentum for cancer vaccine builds
Moderna swings to a profit as momentum builds for its cancer vaccine, according to financial reports.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
HP names former GSK chief Emma Walmsley as CEO
HP Inc. has appointed former GSK chief Emma Walmsley as its new CEO to lead the company's strategic push into AI-powered PCs.